Spectral AI Announces Q3 2024 Financial Results Conference Call

Spectral AI Schedules Q3 2024 Financial Results Call

Spectral AI, Inc. (Nasdaq: MDAI), a Dallas-based artificial intelligence company specializing in medical diagnostics for wound care, has announced the date for its 2024 third quarter financial results release and conference call. The company will disclose its financial performance for the quarter ending September 30, 2024, on Wednesday, November 6, 2024, after the stock market closes 1

1

2

Conference Call Details

Following the release of the financial results, Spectral AI will host a conference call at 5:00 pm Eastern Time on the same day. Investors interested in participating in the live call can dial:

• 833-630-1956 (U.S.)
• 412-317-1837 (International)

For those unable to join the live call, a simultaneous webcast will be accessible from the Events & Presentations section of the company's Investor Relations page at https://investors.spectral-ai.com/news-events/events 1

1

2

About Spectral AI and Its Technology

Spectral AI is focused on revolutionizing wound care management through its innovative DeepView® System. This predictive device utilizes AI to provide clinicians with an objective and immediate assessment of a wound's healing potential prior to treatment or medical intervention 1

1

2

The DeepView® System aims to:

1. Offer algorithm-driven results
2. Exceed the current standard of care
3. Provide faster and more accurate treatment insights
4. Improve patient outcomes
5. Reduce healthcare costs

The company's initial applications involve patients with burns and diabetic foot ulcers, addressing critical areas in medical care where rapid and accurate diagnosis can significantly impact treatment efficacy 1

1

2

Related Stories

Spectral AI Announces Q4 and Full Year 2024 Financial Results Conference Call

Spectral AI Expands Clinical Trial Sites and Strengthens Patent Portfolio

Spectral AI Expands AI-Driven Burn Assessment Technology to Australia

Spectral AI Advances Burn Study with Expanded Clinical Trial Sites and Increased Patient Enrollment

Forward-Looking Statements and Investor Caution

As with many companies in the AI and medical technology sector, Spectral AI's announcements come with forward-looking statements. These statements are subject to various risks and uncertainties that could cause actual results to differ from projections 1

1

2

Investors are advised to carefully consider the risk factors described in the company's SEC filings, including the Registration Statement and other documents. The company emphasizes that these forward-looking statements are not guarantees of future performance and urges readers not to place undue reliance on them 1

1

2

Investor Relations Contact

For those seeking more information, Spectral AI has provided contact details for their investor relations team:

• Devin Sullivan, Managing Director at The Equity Group ([email protected])
• Conor Rodriguez, Analyst at The Equity Group ([email protected]) 2

  2

As Spectral AI prepares to share its Q3 2024 results, the announcement highlights the growing intersection of AI technology and healthcare, particularly in the field of wound care diagnostics and treatment planning.